Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

The tumor development and metastasis are closely related to the structure and function of
the tumor microenvironment (TME). Recently, TME modulation strategies have attracted …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Immune checkpoint inhibitors have revolutionized medical oncology, although currently only
a subset of patients has a response to such treatment. A compelling body of evidence …

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

The recognition of DNA as an immune-stimulatory molecule is an evolutionarily conserved
mechanism to initiate rapid innate immune responses against microbial pathogens. The …

Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …

Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …

Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …